Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II

Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creati...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the American Heart Association Ročník 12; číslo 6; s. e026605
Hlavní autoři:	Yao, Ren Jie Robert, Holmes, DaJuanicia N., Andrade, Jason G., Levin, Adeera, Piccini, Jonathan P., Fordyce, Christopher B.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England John Wiley and Sons Inc 21.03.2023 Wiley
Témata:	Administration, Oral Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Dabigatran Humans nonvitamin K oral anticoagulant ORBIT‐AF II Original Research renal dose adjustment Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - epidemiology Rivaroxaban Stroke - diagnosis Stroke - epidemiology Stroke - etiology ORBIT‐AF II atrial fibrillation nonvitamin K oral anticoagulant renal dose adjustment
ISSN:	2047-9980, 2047-9980
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!